RCS - Abingdon Health PLC - Senzo & Abingdon enter into strategic partnership

Abingdon HealthAnnouncement

20/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230320:nRST4225Ta&default-theme=true

RNS Number : 4225T  Abingdon Health PLC  20 March 2023

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Senzo and Abingdon Health enter into strategic partnership

Abingdon Health's CDMO service to support Senzo in leveraging its innovative,
high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform
technology across multiple product opportunities

 

Senzo Health Limited (London, UK) ("Senzo") and Abingdon Health plc (York, UK)
("Abingdon Health") announce the signing of a strategic partnership agreement.

 

Under the terms of the partnership Abingdon Health will support Senzo by
providing contract development and manufacturing ("CDMO") services to Senzo
and its partners to enable them to develop and manufacture new rapid tests
utilising Senzo's cutting-edge ALF platform.

 

Senzo is a leading innovator in the rapid diagnostics testing market, with its
revolutionary lateral flow technology delivering the same accuracy as
laboratory-based PCR with results available within 10 minutes, at a fraction
of the cost. Senzo Health's technology is initially being applied to the
development of a Covid-19 antigen assay, a broader respiratory panel, and
other infectious disease tests. However, there are a wide range of
applications across clinical, animal health, food, plant pathogen and
environmental testing that would benefit from strengths of Senzo's platform
technology. This strategic partnership will allow Senzo's partners to
accelerate product development through access to Abingdon Health's CDMO
services.

 

Abingdon Health is a leading lateral flow CDMO offering its services to an
international customer base across a range of industry sectors. Abingdon
Health has the internal capabilities to take projects from initial concept
through to routine and large-scale manufacturing; from "idea to commercial
success". All projects are managed through Abingdon Health's quality
management system and its services include feasibility, optimisation,
technical transfer, manufacturing, regulatory and commercial support. Its
UK-based automated manufacturing operations are capable of producing tens of
millions of lateral flow tests per annum.

 

Jeremy Stackawitz, CEO of Senzo Health, commented: "This new partnership, with
such an established, innovative, and trusted group as Abingdon, is a terrific
opportunity for Senzo as we seek to expand the tests being developed and
brought to market on our game-changing ALF platform. Collaborating with
Abingdon creates a valuable synergy for customers looking to bring innovative,
high-performance lateral flow products to market, and we're extremely eager to
get to work on the first assays."

 

Chris Yates, CEO of Abingdon Health, commented: "We are really excited to be
working with Senzo and supporting them in leveraging their cutting-edge
lateral flow platform technology across multiple applications. We believe this
strategic partnership agreement provides Senzo Health and its customers with
access to Abingdon's best-in-class CDMO service to enable accelerated product
development and time to market."

 

Enquiries

 

 Abingdon Health plc                                          www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                         Via Walbrook PR
 Melanie Ross, Chief Financial Officer
                                  Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

 Walbrook PR Limited
 Paul McManus / Phillip Marriage  Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

 Alice Woodings                   +44 (0)7407 804 654

 

About Senzo:

Senzo is an in vitro diagnostics company developing innovative, accurate, and
accessible testing products. Senzo was founded with the vision of utilizing
novel technologies, with a focus on enhanced sensitivity, to create mobile,
point-of-care and self-testing products and devices with the ability to
accurately, quickly, and cost-effectively conduct testing where healthcare
professionals and patients need it most. Senzo is creating game-changing
products and systems which bring testing to the patient, eliminating the need
for the current slow, expensive central-lab testing paradigms. With insights
generated at the point of care, patients can make better decisions faster, and
healthcare professionals can identify life-threatening diseases at an earlier
stage, improving treatment outcomes and saving lives. www.senzo.com
(http://www.senzo.com/)

 

About Abingdon Health plc:

Abingdon Health is a leading lateral flow contract development and
manufacturing organisation ("CDMO") offering its services to an international
customer base across industry sectors that include clinical, animal health,
plant health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) ecommerce site offers consumers a range of
information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUQAWUPWGQM